The estimation of the efficacy of immuno-checkpoint inhibitor in gene mutation for recurrent oral cancer
| Project/Area Number |
19K10337
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Review Section |
Basic Section 57060:Surgical dentistry-related
|
|---|
| Research Institution | Sapporo Medical University |
|---|
Principal Investigator |
Ogi Kazuhiro 札幌医科大学, 医学部, 講師 (40433114)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
西山 廣陽 札幌医科大学, 医学部, 助教 (60749563)
宮本 昇 琉球大学, 医学部附属病院, 助教 (80749565)
|
|---|
| Project Period (FY) |
2019-04-01 – 2023-03-31
|
| Project Status |
Completed (Fiscal Year 2022)
|
| Budget Amount *help |
¥4,420,000 (Direct Cost: ¥3,400,000、Indirect Cost: ¥1,020,000)
Fiscal Year 2021: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2020: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2019: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
|
|---|
| Keywords | Immunotherapy / squamous cell carcinoma / gene mutation / 再発口腔がん / 免疫チェックポイント阻害剤 / 遺伝子変異 / がん免疫環境 / 再発口腔癌 / 免疫チェックポイント阻害薬 / 遺伝子変異量 |
|---|
| Outline of Research at the Start |
我々が開発した口腔癌遺伝子解析パネルをもちいて、口腔扁平上皮癌（凍結組織、FFPE）における遺伝子異常を効率的、かつ低コストで行い、治療抵抗性、再発・予後との相関を分析する。遺伝子異常（遺伝子変異、コピー数異常）は実験的に評価し、口腔癌の発症、進展への関与を解析する。これらの成果をもとに、従来の評価法を補完しうる、血清、末梢循環DNAを用いた、口腔癌の新しい診断・治療予測システムを開発する。本研究の主眼は免疫チェックポイント阻害薬の適応症例を選択するにあたり、遺伝子変異量や新たなneoantigenの存在が潜在マーカーを症例ごとにプロファイリングする。
|
| Outline of Final Research Achievements |
The indications of immune checkpoint inhibitors (ICIs) are mainly for recurrent oral cancer. It carefully requires the assessment of the slowly continuous therapeutic effects after administration of ICIs, and the switching from ICIs to cytotoxic anticancer agents or to molecular-targeted agents. In addition, there are no evidence regarding to the administration period. Also, it shows a delayed effect, and prolong a long time until it occurs a tumor immune response. In our research, we were able to verify the relevance of tumor-infiltrating lymphocytes (TIL) and somatic gene mutations in our clinical specimens, resulting from the exploration of some factors for predicting the therapeutic effect of ICI.
|
| Academic Significance and Societal Importance of the Research Achievements |
再発口腔癌に対して, ICI投与前にがん関連遺伝子変異を調べてICIの有効性を検証することができる. これによりirAEなどの有害事象の軽減に繋がり, がん免疫療法を適正な治療法として確立することができる.
|
Report
(5 results)
Research Products
(14 results)
-
[Journal Article] Prognostic value of CD45Ro＋ T-cell expression in patients with oral squamous cell carcinoma2021
Author(s)
Koike Kazushige, Nishiyama Koyo, Dehari Hironari, Ogi Kazuhiro, Sasaki Takanori, Shimizu Shota, Sasaya Takashi, Tsuchihashi Kei, Sonoda Tomoko, Hasegawa Tadashi, Hiratsuka Hiroyoshi, Miyazaki Akihiro.
-
Journal Title
Anticancer Res.
Volume: 41(9)
Issue: 9
Pages: 4515-4522
DOI
Related Report
Peer Reviewed / Open Access / Int'l Joint Research
-
-
[Journal Article] Prognostic value of HLA class Ⅰ expression in patients with oral squamous cell carcinoma2020
Author(s)
Koike K, Dehari H, Shimizu S, Nishiyama K, Sonoda T, Ogi K, Kobayashi J, Sasaki T, Sasaya T, Tsuchihashi K, Tsukahara T, Hasegawa T, Torigoe T, Hiratsuka H, Miyazaki A
-
Journal Title
Cancer Sci
Volume: in press
Issue: 5
Pages: 1491-1499
DOI
Related Report
Peer Reviewed / Open Access / Int'l Joint Research
-
-
-
-
-
-
-
[Presentation] Prognostic impact of HLA class I expression and its association with CD8 T-cell density in patients with oral squamous cell carcinoma2020
Author(s)
Koike K, Dehari H, Ogi K, Shimizu S, Nishiyama K, Sonoda T, Sasaki T, Sasaya T, Tsuchihashi K, Hasegawa T, Torigoe T, Hiratsuka H, Miyazaki A
Organizer
第79回日本癌学会学術総会
Related Report
-
-
-
-
